The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung
Abstract Background The ex vivo human perfused lung model has enabled optimizing donor lungs for transplantation and delineating mechanisms of lung injury. Perfusate and airspace biomarkers are a proxy of the lung response to experimental conditions. However, there is a lack of studies evaluating bi...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-09-01
|
Series: | Intensive Care Medicine Experimental |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40635-020-00343-x |
id |
doaj-a08880b4464742ef9ad6e5115079c5bc |
---|---|
record_format |
Article |
spelling |
doaj-a08880b4464742ef9ad6e5115079c5bc2020-11-25T03:13:17ZengSpringerOpenIntensive Care Medicine Experimental2197-425X2020-09-018111510.1186/s40635-020-00343-xThe endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lungAleksandra Leligdowicz0James T. Ross1Nicolas Nesseler2Michael A. Matthay3Cardiovascular Research Institute, University of California, San FranciscoDepartment of Surgery, University of California, San FranciscoCardiovascular Research Institute, University of California, San FranciscoCardiovascular Research Institute, University of California, San FranciscoAbstract Background The ex vivo human perfused lung model has enabled optimizing donor lungs for transplantation and delineating mechanisms of lung injury. Perfusate and airspace biomarkers are a proxy of the lung response to experimental conditions. However, there is a lack of studies evaluating biomarker kinetics during perfusion and after exposure to stimuli. In this study, we analyzed the ex vivo-perfused lung response to three key perturbations: exposure to the perfusion circuit, exogenous fresh whole blood, and bacteria. Results Ninety-nine lungs rejected for transplantation underwent ex vivo perfusion. One hour after reaching experimental conditions, fresh whole blood was added to the perfusate (n = 55). Two hours after reaching target temperature, Streptococcus pneumoniae was added to the perfusate (n = 42) or to the airspaces (n = 17). Perfusate and airspace samples were collected at baseline (once lungs were equilibrated for 1 h, but before blood or bacteria were added) and 4 h later. Interleukin (IL)-6, IL-8, angiopoietin (Ang)-2, and soluble tumor necrosis factor receptor (sTNFR)-1 were quantified. Baseline perfusate and airspace biomarker levels varied significantly, and this was not related to pre-procurement PaO2:FiO2 ratio, cold ischemia time, and baseline alveolar fluid clearance (AFC). After 4 h of ex vivo perfusion, the lung demonstrated a sustained production of proinflammatory mediators. The change in biomarker levels was not influenced by baseline donor lung characteristics (cold ischemia time, baseline AFC) nor was it associated with measures of experimental epithelial (final AFC) or endothelial (percent weight gain) injury. In the presence of exogenous blood, the rise in biomarkers was attenuated. Lungs exposed to intravenous (IV) bacteria relative to control lungs demonstrated a significantly higher rise in perfusate IL-6. Conclusions The ex vivo-perfused lung has a marked endogenous capacity to produce inflammatory mediators over the course of short-term perfusion that is not significantly influenced by donor lung characteristics or the presence of exogenous blood, and only minimally affected by the introduction of systemic bacteremia. The lack of association between biomarker change and donor lung cold ischemia time, final alveolar fluid clearance, and experimental percent weight gain suggests that the maintained ability of the human lung to produce biomarkers is not merely a marker of lung epithelial or endothelial injury, but may support the function of the lung as an immune cell reservoir.http://link.springer.com/article/10.1186/s40635-020-00343-xBiomarkersEx vivo-perfused lungStreptococcus pneumoniaeARDSLung transplant |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aleksandra Leligdowicz James T. Ross Nicolas Nesseler Michael A. Matthay |
spellingShingle |
Aleksandra Leligdowicz James T. Ross Nicolas Nesseler Michael A. Matthay The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung Intensive Care Medicine Experimental Biomarkers Ex vivo-perfused lung Streptococcus pneumoniae ARDS Lung transplant |
author_facet |
Aleksandra Leligdowicz James T. Ross Nicolas Nesseler Michael A. Matthay |
author_sort |
Aleksandra Leligdowicz |
title |
The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung |
title_short |
The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung |
title_full |
The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung |
title_fullStr |
The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung |
title_full_unstemmed |
The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung |
title_sort |
endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung |
publisher |
SpringerOpen |
series |
Intensive Care Medicine Experimental |
issn |
2197-425X |
publishDate |
2020-09-01 |
description |
Abstract Background The ex vivo human perfused lung model has enabled optimizing donor lungs for transplantation and delineating mechanisms of lung injury. Perfusate and airspace biomarkers are a proxy of the lung response to experimental conditions. However, there is a lack of studies evaluating biomarker kinetics during perfusion and after exposure to stimuli. In this study, we analyzed the ex vivo-perfused lung response to three key perturbations: exposure to the perfusion circuit, exogenous fresh whole blood, and bacteria. Results Ninety-nine lungs rejected for transplantation underwent ex vivo perfusion. One hour after reaching experimental conditions, fresh whole blood was added to the perfusate (n = 55). Two hours after reaching target temperature, Streptococcus pneumoniae was added to the perfusate (n = 42) or to the airspaces (n = 17). Perfusate and airspace samples were collected at baseline (once lungs were equilibrated for 1 h, but before blood or bacteria were added) and 4 h later. Interleukin (IL)-6, IL-8, angiopoietin (Ang)-2, and soluble tumor necrosis factor receptor (sTNFR)-1 were quantified. Baseline perfusate and airspace biomarker levels varied significantly, and this was not related to pre-procurement PaO2:FiO2 ratio, cold ischemia time, and baseline alveolar fluid clearance (AFC). After 4 h of ex vivo perfusion, the lung demonstrated a sustained production of proinflammatory mediators. The change in biomarker levels was not influenced by baseline donor lung characteristics (cold ischemia time, baseline AFC) nor was it associated with measures of experimental epithelial (final AFC) or endothelial (percent weight gain) injury. In the presence of exogenous blood, the rise in biomarkers was attenuated. Lungs exposed to intravenous (IV) bacteria relative to control lungs demonstrated a significantly higher rise in perfusate IL-6. Conclusions The ex vivo-perfused lung has a marked endogenous capacity to produce inflammatory mediators over the course of short-term perfusion that is not significantly influenced by donor lung characteristics or the presence of exogenous blood, and only minimally affected by the introduction of systemic bacteremia. The lack of association between biomarker change and donor lung cold ischemia time, final alveolar fluid clearance, and experimental percent weight gain suggests that the maintained ability of the human lung to produce biomarkers is not merely a marker of lung epithelial or endothelial injury, but may support the function of the lung as an immune cell reservoir. |
topic |
Biomarkers Ex vivo-perfused lung Streptococcus pneumoniae ARDS Lung transplant |
url |
http://link.springer.com/article/10.1186/s40635-020-00343-x |
work_keys_str_mv |
AT aleksandraleligdowicz theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT jamestross theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT nicolasnesseler theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT michaelamatthay theendogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT aleksandraleligdowicz endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT jamestross endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT nicolasnesseler endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung AT michaelamatthay endogenouscapacitytoproduceproinflammatorymediatorsbytheexvivohumanperfusedlung |
_version_ |
1724647633865146368 |